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Artificial metalloenzymes that contain protein-anchored synthetic catalysts are attracting in-
creasing interest. An exciting, but still unrealised advantage of non-covalent anchoring is its 
potential for reversibility and thus component recycling. Here we present a siderophore-protein 
combination that enables strong but redox-reversible catalyst anchoring, as exemplified by an 
artificial transfer hydrogenase (ATHase). By linking the iron(III)-binding siderophore azoto-
chelin to an iridium-containing imine-reduction catalyst that produces racemic product in the 
absence of the protein CeuE, but a reproducible enantiomeric excess if protein bound, the as-
sembly and reductively-triggered disassembly of the ATHase was achieved. The crystal struc-
ture of the ATHase identified the residues involved in high-affinity binding and enantioselectivi-
ty. Whilst in the presence of iron(III) the azotochelin-based anchor binds CeuE with high affini-
ty, the reduction of the coordinated iron(III) to iron(II) triggers its dissociation from the protein. 




The development of artificial metalloenzymes is a rapidly expanding field, with design strate-
gies ranging from the modification of natural metalloenzymes through to complete de novo de-
sign (Fig. 1a).1-7 Of these, the anchoring strategy, in which a synthetic catalyst is attached to a 
protein scaffold, has drawn much attention since it allows the reactivity of organometallic cata-
lysts to be harnessed in a biocompatible and (stereo)selective protein environment.8-10 In con-
trast to covalent anchoring, non-covalent anchoring does not rely on reactive functional groups 
for bond formation, and hence it allows the individual components, in particular the catalytic 
site and the protein scaffold to be optimised independently, before the artificial enzyme is as-
sembled and further optimised as a whole.8, 11, 12 This advantage of non-covalent anchoring 
has been exploited extensively, mainly by utilising the streptavidin-biotin affinity pair,8, 13-16 
while enzyme-inhibitor and myoglobin-heme combinations17-19 have also been explored.  
Whilst these affinity pairs benefit from the enormous binding strength that cooperative non-
covalent interactions can confer, their potential for controlled reversibility has not yet been ac-
complished. Yet, anchoring should be a reversible process that allows the anchor to be de-
tached when required. Hence, for modularly-designed artificial enzymes to reach their full po-
tential, a strong but reversible anchoring process is required, which enables both the con-
trolled assembly and disassembly of the components. Controlled reversibility would allow the 
recycling of both protein scaffold and artificial metal cofactor. The controlled release and re-
placement of a catalyst should enable exciting new applications in biosensing and (mi-
cro)fluidic devices, especially when the protein scaffold is immobilised. Hence, much effort has 
been devoted to achieving reversibility with biotin derivatives20 and alternatives21 or 




Siderophores and their cognate periplasmic binding proteins (PBPs)23 on the other hand, 
have properties that are well suited to the development of redox-reversible anchoring systems.
Siderophores are produced by microorganisms for the uptake of essential iron(III) and the iron 
complexes of siderophores are bound strongly, but reversibly, by their cognate PBPs.24-27 In-
side the cell, the prominent mechanism for the release of iron from siderophores is reduction 
of the coordinated iron(III) to iron(II). Iron release from the siderophore is facilitated asthe re-
sulting iron(II)-siderophore complexes have a lower thermodynamic stability and are kinetically 
more labile than their Fe(III) counterparts.25, 26, 28 We previously reported that CeuE, an iron-
siderophore PBP of Campylobacter jejuni, has high affinity for the iron(III) complex of the 
tetradentate siderophore bis(2, 3-dihydroxy-benzoyl-L-Ser) (H5-bisDHBS, 1, Fig. 1b), based on 




Figure 1. Design considerations. a, Strategies for the development of artificial metalloen-
zymes. b, Structures of bis(2, 3-dihydroxy-benzoyl-L-Ser) (H5-bisDHBS) 1, and azotochelin 
(H5-AZOTO) 2. c, Detail of the crystal structure of [FeIII(AZOTO)]2-⊂CeuE (PDB 5OAH) illus-
trating tetradentate siderophore binding. Two protein side chains, Tyr288 and His227, com-
plete the coordination sphere of the iron (CeuE: electrostatic surface representation; Fe pur-
ple; C green (His227, Tyr288) or grey (azotochelin); remaining atoms of siderophore and Fe-
coordinating residues coloured by atom type). d, Siderophore-anchored metalloenzyme de-
sign: CeuE (blue and green), iron(III) complex of a tetradentate siderophore (purple) and at-
tached transfer hydrogenation catalyst (orange).
 
 
Here we show how this binding mode can be exploited in the development of a redox-
switchable iron-siderophore anchor that allows the reversible attachment of synthetic catalysts 
to CeuE. To monitor whether the synthetic catalyst is turning over in its protein-bound form or, 
after release, in its unbound state, we chose the transfer hydrogenation of a pro-chiral imine 
as indicator reaction and a racemate-producing organometallic complex as the initial model 
catalyst. In this system, the interactions of the catalyst with the chiral protein scaffold are re-
flected in the level of enantioselectivity observed. The choice of catalyst was based on the 
suitability of similar catalysts in the development of previously reported enantioselective artifi-
cial transfer hydrogenases.31-33  
 
RESULTS   
Anchor Design. 
Since the tetradentate siderophore 1 that we studied initially is challenging to synthesise and 
hydrolytically unstable, azotochelin, 2 (Fig. 1b), the siderophore of Azotobacter vinelandii was 
 
selected instead. Azotochelin was synthesised as previously described34 and the affinity of its 
Fe(III) complex for CeuE was determined via intrinsic fluorescence quenching (see Supple-
mentary Methods). With 4.9 ± 0.4 nM, its dissociation constant compares favourably with 
those reported for artificial enzymes that rely on biotin as anchoring unit (e.g. biotinylated Hov-
eyda-Grubbs catalystavidin: Kd = 6.3 nM)35 or enzyme inhibitors (e.g. sulfonamide-bearing 
transfer hydrogenation catalysthCA II: Kd = 15 nM).17 In contrast, the affinities of apo-
azotochelin and Fe(II)-azotochelin for CeuE were too low to be determined in this concentra-
tion range (Kd = >1 µM, Supplementary Fig 1). 
To reveal the interactions between [FeIII(AZOTO)]2- and CeuE, [FeIII(AZOTO)]2- was soaked 
into crystals of apo-CeuE (PDB code 3ZKW) and the structure of the resulting complex, 
[FeIII(AZOTO)]2-⊂CeuE, was determined. The structure (PDB code 5OAH, Supplementary 
Methods and Supplementary Fig. 2 ) showed that the four catecholate oxygen donors of 
azotochelin coordinate to the Fe(III) centre with the remaining coordination sites being occu-
pied by the donors of His227 and Tyr288 (Fig. 1c). The carboxylate group in the backbone of 
the siderophore was deemed appropriate as a conjugation site for the attachment of a catalyst 
since it remains uncoordinated and points away from the binding site.  
The reductively-triggered dissociation of the iron(III) complex of azotochelin was then investi-
gated (Fig. 2). First, the iron(III) centre of [FeIII(AZOTO)]2-⊂CeuE was reduced to iron(II) by 
addition of sodium dithionite, as evidenced by the bleaching of the broad catecholate-to-
iron(III) charge transfer band in the electronic absorption spectrum of the complex (λmax 547 
nm, Fig. 2a). The subsequent addition of an aliquot of the reduced sample (Fig. 2b) to fer-
rozine,28, 36 an iron(II) indicator, led to the formation of the intensely-coloured magenta iron(II)-
ferrozine complex (Fig. 2c, d), confirming that the reduction to iron(II) is followed by its dissoci-
ation from both the siderophore anchor and CeuE. The re-oxidation of iron(II) to iron(III) was 
achieved by exposure to air and the reassembly of the azotochelin complex was confirmed by 
 
the reappearance of its characteristic absorption band. The absorption maximum at 543 nm 
resembles that of [Fe(AZOTO)]2-⊂CeuE (λmax 547 nm) rather than that of free [Fe(AZOTO)]2- 
(λmax 572 nm). Addition of ferrozine to the re-oxidised solution confirmed the absence of resid-
ual iron(II) (Fig. 2e).  
 
 
Figure 2. Redox-switchable siderophore anchoring. a-e. Reductively-triggered dissocia-
tion of [FeIII(AZOTO)]2-⊂CeuE and its oxidatively-triggered reassembly, 0.1 M MES, 0.5 M 
NaCl, pH 6.0: CeuE (blue), iron(III) (purple), azotochelin (black + red), iron(II) (white/grey), as 
monitored by visible absorption spectroscopy ([FeIII(AZOTO)]2-⊂CeuE: λmax = 547 nm, Fe(II)-
ferrozine: λmax  563 nm). Due to the intense magenta colour of the iron(II)-ferrozine indicator 




Figure 3. Catalyst development and conjugate synthesis. a, Structures of transfer hydro-
genation catalysts 3 and 6. b, Kinetic profiles for the reduction of 4 (50 mM) to (RS)-5 for cata-
lysts 3 (red diamonds) and 6 (blue triangles), both at 0.5 mM in 0.6 M MES, pH 6.5, 3 M sodi-
um formate, 40 °C. c, Synthesis of conjugate H5-11 and [FeIII(solv)2(11)Cp*IrIIICl]-, with solv = 
solvent molecule. Conditions: i) 2-(aminomethyl)pyridine, NEt3, CH2Cl2, 78%; ii) LiBH4, MeOH, 
THF, 68%; iii) Bn4-AZOTO, EDC, HOBt, NEt3, DMF, 47%; iv) H2, Pd-(OH)2/C 20%, EtOH, 95%. 
 
 
Design, Synthesis and Characterisation of the Artificial Transfer Hydrogenase. Inspired 
by previous work on ATHases by Ward et al.,8 we initially prepared the Noyori-Ikariya-type cat-
alyst 3, which was able to catalyse the reduction of 4 to (RS)-salsolidine (5), but the slow reac-
tion rate was impractical (Fig. 3b). In search of a more active catalyst, we considered 
 
[Cp*Ir(pyridinesulfonamide)Cl] complexes, which have shown promise in the transfer hydro-
genation of ketones and aldehydes with 2-propanol.37, 38  Encouraged by studies reported by 
Sadler et al.39 and Wills et al.,40 we reasoned that for the reduction of 4 at pH 6.5, an iridium-
coordinated amine group would not be required as proton donor. Under these conditions, 4 is 
protonated and could either react directly with a metal-coordinated hydride39 or hydrogen bond 
with the sulfonyl group of the ligand.41 Hence we replaced the amine group in 3 with a pyridyl 
group 6 (Fig. 3a). In comparison with 3, 6 shows a significantly enhanced reaction rate for the 
reduction of 4 to (RS)-5 (Fig. 3b). 
 
Figure 4. Characterisation of [FeIII(AZOTO)]2-⊂CeuE and [FeIII(11)Cp*IrIII]⊂CeuE. a, Fluo-
rescent quenching observed upon addition of [FeIII(AZOTO)]2-, [FeIII(11)Cp*IrIII] or 12 to CeuE 
(40 mM Tris-Cl pH 7.5, 150 mM NaCl). b, CD spectra of [FeIII(AZOTO)]2- and [FeIII(11)Cp*IrIII] 
in the presence or absence of CeuE, with a control spectrum for CeuE alone. c, Crystal struc-
 
ture of [FeIII(11)Cp*IrIII]⊂CeuE (PDB code 5OD5; CeuE ribbon representation; Fe purple; Ir 
coral; C green (His227, Tyr288) or grey (11, Cp*) remaining atoms coloured by type). d, Detail 
of the crystal structure of [FeIII(11)Cp*IrIII]⊂CeuE (CeuE: electrostatic surface representation). 
e, ORTEP plot of (R)-[Cp*IrIII(8)Cl], 12 (50% probability ellipsoids, H atoms omitted for clarity, 
CCDC 1551724). 
 
To improve the nucleophilicity of the nitrogen atom in 6, a methylene group was inserted to 
give 9, with which the amide bond formation to produce 10 proceeded in good yields (Fig. 3c). 
[FeIII(solv)2(11)Cp*IrIIICl]- was obtained by reacting the deprotected conjugate H5-11 with 
iron(III), followed by iridium(III). 
Finally, CeuE was added to prepare the ATHase, which was characterised by electrospray 
ionisation mass spectrometry (ESI-MS; Supplementary Methods, Supplementary Fig. 3). Sig-
nals at 32024.4 and 33078.4 Da are consistent with CeuE and [FeIII(11)Cp*IrIII]⊂CeuE (theo-
retical average molecular masses of 32024.0 and 33079.0 Da, respectively). Interestingly, the 
mass spectra suggest loss of the iridium-coordinated chloride ligand upon protein binding. The 
dissociation constant of [FeIII(11)Cp*IrIII]⊂CeuE confirmed that the iron-siderophore anchor of 
the conjugate still binds CeuE with suitably high affinity (Kd = 18.3 ± 4.9 nM, Fig. 4a).  
In view of the envisaged application of the artificial enzyme in asymmetric catalysis, it was of 
interest to investigate the stereochemistry of the conjugate. In [FeIII(11)Cp*IrIII]⊂CeuE the iron 
and iridium centres can adopt Λ/Δ- or R/S-configurations, respectively, with the diastereomeric 
ratio affected by both intramolecular asymmetric induction by the L-lysine backbone and the 
interactions with the chiral protein binding pocket. It was previously observed that CeuE drives 
the diastereomeric equilibration of [Fe(bisDHBS)]2- by selecting for Λ-configured iron(III) cate-
cholates.29, 30, 42, 43 Therefore, we probed the stereochemistry of the metal centres in 
[FeIII(AZOTO)]2- and [FeIII(solv)2(11)Cp*IrIIICl]- by recording circular dichroism (CD) spectra, 
 
both in the absence and presence of CeuE. In the absence of CeuE, the CD spectra of both 
complexes display a positive band between 330 nm and 335 nm and a very weak positive 
band at around 600 nm (Fig. 4b), which can be assigned to ligand-based transitions and lig-
and-to-metal charge-transfer (LMCT) transitions, respectively.44 Since the latter reflect the chi-
rality at the iron(III) centre, the low intensity of the LMCT band is indicative of a weak asym-
metric induction effect exerted by the L-lysine backbone in [FeIII(AZOTO)]2- and 
[FeIII(solv)2(11)Cp*IrIIICl]-. 
In contrast, in the presence of CeuE, the CD spectra of [FeIII(AZOTO)]2-⊂CeuE and 
[FeIII(11)Cp*IrIII]⊂CeuE show features consistent with the majority of the iron(III) centres adopt-
ing Λ-configuration44 and confirm that the diastereomers in solution equilibrate quickly. Unfor-
tunately, assignment of configuration to the iridium centre in [FeIII(11)Cp*IrIII]⊂CeuE was pre-
vented by the dominant iron-azotochelin chromophore.  
 
Crystal Structure of [FeIII(11)Cp*IrIII]⊂CeuE. [FeIII(solv)2(11)Cp*IrIIICl]- was soaked into a 
crystal of apo-CeuE (PDB code 3ZKW) and the structure was determined by X-ray crystallog-
raphy. Experimental details are provided in the Supplementary Methods. The crystal is in 
space group P1 with three independent protein chains (A, B and C) in the asymmetric unit. 
The following description focuses on chain C, which shows the clearest additional electron 
density in the binding pocket (Fig. 4c, d). 
As seen previously, the azotochelin moiety chelates a Λ-configured iron centre.29, 30 Howev-
er, the flexible loop containing His227, which coordinates to the iron in [FeIII(AZOTO)]2-⊂CeuE, 
is displaced by the catalyst and the sixth coordination site is occupied by an aqua/hydroxo lig-
and.  
While the azotochelin moiety is well-ordered and modelled with full occupancy, the catalyst 
moiety of [FeIII(11)Cp*IrIII] adopts more than one conformation, evidenced by the anomalous 
 
difference map (Supplementary Fig 4). The major conformation of the catalyst moiety was 
modelled with an occupancy of 0.6.  
The crystal structure of a related iridium catalyst was independently determined (12, Fig. 4e, 
CCDC 1551724) in a centric space group which thus contained both enantiomers. The geo-
metric parameters from this structure were used as restraints in the building and refinement of 
the conjugate complex model. During the modelling of the major conformation, we were en-
couraged to find that only one enantiomer gave a satisfactory fit to the density. This provides a 
potential explanation for the observed enantioselectivity of the protein-bound catalyst (vide in-
fra), the protein imposing a preference for one of the two chiral forms. While the electron den-
sity is low for the Cp* ring and parts of the catalyst, difference maps confirmed their approxi-
mate location (Supplementary Fig. 5). Similar partial occupancies have previously been ob-
served in crystal structures of ATHases with anchored iridium-based catalysts.17, 32 
In [FeIII(11)Cp*IrIII]⊂CeuE, His227 cannot coordinate to the iron since its access is blocked 
by the catalyst, and instead appears to lie close to the iridium centre and may well be coordi-
nated to it (Supplementary Fig. 6). If it is coordinated, one of the ligands, most likely His227, is 
required to dissociate to enable hydride coordination during catalysis, and the flexibility of the 
loop on which His227 is located may make such a movement possible. There is no indication 
in the structure of an iridium-bound chloride ion, consistent with the mass spectrometry results. 
Interestingly, dual anchoring via coordination of a suitably-positioned histidine residue to the 
catalyst was previously reported to enhance the enantioselectivity of a biotin-anchored 
ATHase.31 In that study, the catalyst was linked to the biotin anchor through the Cp* ligand and 
the histidine remains coordinated during the catalytic cycle, with the incoming hydride replac-
ing an iridium-bound chloride ligand instead.  
 
 
Transfer Hydrogenation Catalysis. Catalytic activity tests confirmed that 
[FeIII(11)Cp*IrIII]⊂CeuE is able to catalyse the reduction of 4 to 5, with the reaction reaching 
completion within 24 hours (Table 1). The turnover frequency (TOF) is around 20-fold lower 
than the TOF achieved with [FeIII(solv)2(11)Cp*IrIIICl]- in the absence of CeuE, consistent with 
His227 either competing with the hydride for iridium binding and/or sterically restricting the ac-
cess of the substrate. However, some of the activity decrease is due to the conjugation of the 
catalyst to the anchor, as reflected by the lower activity of [FeIII(solv)2(11)Cp*IrIIICl]- compared 
with 6. In addition, the presence of the protein causes a reduction in activity for both 6 and 
[FeIII(solv)2(11)Cp*IrIIICl]-. 
 
Table 1. Catalytic activity towards reduction of 4 to 5.  
Catalyst TOF/min-1 ta/h eeb/% 
6 




25.1 ± 0.3 (5 min) 
5.9 ± 0.1 (15 min) 
6.0 ± 0.3 (15 min) 
0.30 ± 0.01 (8 h) 






< 3  
< 3  
< 3  
35.4 ± 0.1 (R) 
3.3 ± 0.5 (R) 
0.6 M MES buffer, pH 6, 3 M HCOONa, 40 °C, 50 mM substrate, 
0.125 mM catalyst, measurements were carried out as independent 
triplicates, the uncertainty in the average is indicated as 
(range/2)/(SQRT(3)), TON at completion: 400. aTime to completion. 






Figure 5. Catalytic activity of [FeIII(11)Cp*IrIII]⊂CeuE and control compounds. a, Kinetic 
profile for the formation of (RS)-5 catalysed by [FeIII(11)Cp*IrIII]⊂CeuE (blue circles) and 
[FeIII(11)Cp*IrIII]⊂H227A (green diamonds). Kinetic profiles of control reactions with 6 (grey hol-
low triangles), 6 + CeuE (red hollow circles) and [FeIII(solv)2(11)Cp*IrIIICl]- (black stars) over a 
shorter time scale are shown in the inset. b, Chiral HPLC traces obtained during the reduction 
of 4 (50 mM) to (R)- and (S)-5 catalysed by [FeIII(11)Cp*IrIII]⊂CeuE, 0.125 mM (0.25 mol%) in 
0.6 M MES pH 6, 3 M HCOONa, 40 °C. 
 
Nevertheless it is encouraging that [FeIII(11)Cp*IrIII]⊂CeuE shows significant and reproducible 
enantioselectivity in favour of the (R) enantiomer of 5. The enantiomeric excess obtained (ee 
35%) lies within the range reported for other ATHases prior to genetic optimisation.17, 32, 45 If 6 
is used in the presence of CeuE, (R)-5 and (S)-5 are produced unselectively (Table 1). A simi-
lar lack of enantioselectivity is seen when [FeIII(solv)2(11)Cp*IrIIICl]- is used in the absence of 
 
CeuE. Hence, chiral induction by the L-lysine backbone of azotochelin is insignificant. These 
observations confirm that the siderophore-mediated anchoring to CeuE is required to achieve 
enantioselectivity, since it positions the catalyst within the chiral environment provided by the 
protein. To gauge the contribution of the His227 to the enantioselectivity, it was replaced with a 
non-coordinating residue, as previously described.43 The mutation of His227 to alanine 
(H227A) resulted in a clear drop in the ee to approximately 3%, whilst the catalytic rate in-
creased to around a third of the free conjugate. This suggests that whilst His227 impedes the 
catalysis to a significant extent, potentially by coordinating to the iridium centre, it is responsi-
ble for a large portion of the enantioselectivity.  
 
Release of the Siderophore-anchored Catalyst and ATHase Re-assembly . Sodium di-
thionite was added to [FeIII(11)Cp*IrIII]⊂CeuE until the bleaching of the catecholate-to-iron(III) 
charge-transfer band confirmed that the reduction had gone to completion (λmax 547 nm, Fig. 
6a-c  and Supplementary Fig. 7). The separation of the reductively released iron(II) and the 
azotochelin-catalyst conjugate from CeuE was achieved by centrifugal microfiltration (details in 
the Supplementary Methods). Once SDS-PAGE (Supplementary Fig. 8a), CD (Supplementary 
Fig. 8b) and UV/vis spectroscopy confirmed that the recovered CeuE was intact, correctly 
folded and free of residual azotochelin-catalyst conjugate, [FeIII(11)Cp*IrIII]⊂CeuE was reas-
sembled by addition of a fresh aliquot of [FeIII(solv)2(11)Cp*IrIIICl]-. The activity of the reassem-
bled ATHase was confirmed in subsequent catalytic runs. Whilst the %conversion obtained 
with the recycled protein was slightly lower than that seen pre-recycling, the stereo-directing 
effect of the protein was fully restored (ee 32%, Fig. 6d).  
The recovery of the azotochelin-catalyst conjugate from the spin filtrate proved challenging 
due to adsorption by the semipermeable membrane of the cut-off filter. If required, it is possi-
ble to partially recover functional catalyst conjugate by extraction of the reduced artificial en-
 
zyme solution with ethyl acetate, followed by HPLC (Recovery yields: iridium-bound azoto-
chelin-catalyst conjugate 11%, H5-11 15%; Supplementary Methods, Supplementary Fig. 9). 
However, the extraction with ethyl acetate leads to the precipitation of CeuE and the recovery 
yield is low. Consequently, the current system allows the recycling of either the protein or a 
fraction of the conjugate, but not both at the same time. 
Further recycling studies are underway and are directed towards siderophore-catalyst conju-
gates, in which the catalyst is linked to the siderophore through the Cp ligand. The aim is to 
not only improve the solubility profile of the conjugates, but to also allow His227 to remain co-
ordinated during the catalytic cycle and thus to increase the catalytic activity and ee. 
 
Figure 6. Redox-switchable anchoring enables CeuE recycling. a, Reduction-triggered 
dissociation of [FeIII(11)Cp*IrIII]⊂CeuE followed by CeuE recovery and ATHase re-assembly, as 
monitored by absorption spectroscopy  ([FeIII(11)Cp*IrIII]⊂CeuE λmax = 547 nm): CeuE (blue), 
iron(III) (purple), azotochelin with attached catalyst (black + yellow), iron(II) (white/grey); 0.1 M 
 
MES, pH 6.0, 0.5 M NaCl. b, Catalytic assay conditions as in Figure 5, but with reduced cata-
lyst concentration of 0.05 mM (0.1 mol%) ATHase (experiments with recycled CeuE were per-
formed in triplicate, error bars show min. and max. values). 
 
CONCLUSIONS 
We have identified azotochelin and CeuE as a siderophore-protein combination that allows 
an iridium-based transfer hydrogenation catalyst to be anchored both strongly and reversibly, 
via the iron complex of the siderophore. Proof-of-concept was demonstrated by means of a 
prototype ATHase, [FeIII(11)Cp*IrIII]⊂CeuE, which was characterised by mass spectrometry, 
CD spectroscopy and X-ray crystallography and shown to catalyse the reduction of a prochiral 
imine with reproducible enantioselectivity. The crystal structure of the ATHase revealed that 
His227 is located close to the catalytic iridium(III) centre. This observation, together with the 
fact that its replacement with alanine results in a clear decrease in ee strongly suggests that 
His227 forms a key part of the chiral binding pocket responsible for the enantioselectivity.  
Since the product obtained in the absence of the protein scaffold is essentially racemic, the 
transfer hydrogenation reaction provided a means of differentiating the CeuE-bound state of 
the siderophore-catalyst conjugate from its unbound state. This demonstrates that the inser-
tion of the conjugate into the protein scaffold can be controlled via the oxidation state of the 
iron. In the presence of iron(III), the azotochelin-based anchor binds strongly to CeuE, but the 
anchor can be released via reduction of iron(III) to iron(II).  
In this way, catalytic centres that have lost activity, for example due to poisoning or decom-
position, could easily be removed and then replaced by a new active catalyst, thereby allowing 
the protein scaffold to be reused. In addition, there is scope for the introduction of other cata-
lysts with similar piano-stool structures. Hence, we propose that the redox-switchable nature of 
ferric-azotochelin anchoring, if combined with a modular approach to enzyme design, could 
 
extend the range of applications in which artificial enzymes can be utilised. If, for example, 
CeuE was to be immobilised on a surface, controlled redox switching, either electrochemically 
or chemically, could be used to reversibly bind a chosen catalyst where and when required, 
allowing biosensor arrays or discovery flow systems to be developed. Catalyst exchange via 
redox switching would thus allow the re-patterning and re-programming of a given platform.  
Opportunities to widen the scope of the reversible anchoring approach include the explora-
tion of similar tetradentate siderophores, initially in combination with other catecholate sidero-
phore-binding proteins, in particular those with iron-coordinating Tyr and His residues. 29, 30 
Looking forward, it would be of interest to engineer suitable amino acid combinations into the 
binding pockets of unrelated proteins. Therefore, our feasibility study is expected to open up 
interesting new prospects in artificial enzyme research. 
 
METHODS 
Compound synthesis and characterisation: 
General methods. 1H and 13C NMR spectra were recorded on a Jeol ECS 400 (400 MHz for 
1H, 100 MHz for 13C) at ambient temperature. Chemical shifts are reported relative to residual 
solvent peaks and coupling constants (J) are given in Hz. High resolution electrospray ioniza-
tion (ESI) mass spectra were recorded on a Bruker microTOF electrospray mass spectrome-
ter. Infra-red (IR) spectra were recorded on a PerkinElmer Spectrum Two (ATIR), covering a 
wavenumber range of 4000-450 cm-1. Elemental analyses were carried out on an Exeter CE-
440 elemental analyser. The circular dichroism spectroscopic measurements were performed 
on a Jasco J810 CD spectropolarimeter at 20 °C under constant nitrogen flush and the specific 
rotation was recorded on a Jasco DIP-370 digital polarimeter. Fluorescence spectra were rec-
orded on a Hitachi F-4500 fluorescence spectrophotometer. Analytical thin layer chromatog-
raphy was performed using Merck silica gel 60 F253 aluminium-backed plates using specified 
 
solvent systems and visualised using a Chromato-vue Model CC-10 ultraviolet lamp. Flash 
column chromatography was carried out using Fluka Silica, pore size 60 Å, 220-440 mesh, 35-
75 μm.   
Compound 8. 4-Cyanobenzenesulfonyl chloride (7, 11 mmol, 2.21 g) suspended in 100 mL of 
dichloromethane was added dropwise to a stirred solution of 2-(aminomethyl)pyridine (10 
mmol, 1 mL) and triethylamine (20 mmol, 2.8 mL) in 250 mL dichloromethane cooled on ice. 
The solution was allowed to warm to room temperature over 4 hours and stirred overnight. The 
solution was concentrated to approximately 100 mL and washed with water (3 x 30 mL) fol-
lowed by brine (1 x 25 mL). The organic layer was dried with MgSO4 and the solvent dried in 
vacuo. The crude product was recrystallised with hot ethyl acetate using hexanes as an anti-
solvent to afford 8 as a beige powder (2.13 g, 7.84 mmol, 78%).  
TLC (CHCl3:MeOH, 10:1 v/v): Rf = 0.43; 1H NMR (400 MHz, (CD3)2SO): δ 8.64 (t, J = 6.0 Hz, 
1H), 8.38 (d, J = 4.4 Hz, 1H), 8.02 (d, J = 8.0 Hz, 2H), 7.91 (d, J = 8.8 Hz, 2H), 7.70 (td, J = 
7.4, 2.0 Hz, 1H), 7.30 (d, J = 8.4 Hz, 1H), 7.22 (dd, J = 7.2, 5.2 Hz, 1H), 4.16 (d, J = 6.4 Hz, 
2H); 13C NMR (100 MHz, (CD3)2SO): δ 156.6, 148.8, 144.9, 136.7, 133.3, 127.3, 122.5, 121,8, 
117.8, 114.7, 47.9; IR (ATIR): 2233 cm-1 (CN); HRMS (m/z): [M+H]+ calcd. for C13H11N3O2S, 
274.0645; found, 274.0643; analysis (calcd., found for C13H11N3O2S): C(57.13, 56.94), H(4.06, 
4.20), N(15.37, 15.15).  
Compound 9. A solution of 8 (2.7 mmol, 0.744 g) in 15 mL dry THF was placed under a nitro-
gen atmosphere. Lithium borohydride (27.2 mmol, 6.8 mL of a 4 M THF solution, Acros Organ-
ics) was added to this stirred solution and the resulting solution was heated to reflux. Once at 
reflux, dry methanol (81 mmol, 3.3 mL) was added over approximately 5 hours (gas evolution 
upon addition) and the solution was refluxed overnight under a nitrogen atmosphere. This was 
followed by addition of an extra 5 mL of dry methanol before the solution was slowly cooled to 
 
room temperature. Deionised water (33 mmol, 0.6 mL) was added and the mixture stirred for 
one hour before the flask was opened to atmosphere. MgSO4 was added, and the suspension 
filtered. The solvent was removed in vacuo to yield a crude white solid, which was suspended 
in EtOAc:MeOH (2:1, v:v) and applied to a short silica plug, washed with EtOAc (100%), and 
the product eluted with EtOAc:MeOH (2:1, v:v). The solvent was removed in vacuo to yield 9 in 
form of a white solid (0.531 g, 1.91 mmol, 70%). 
TLC (EtOAc 100%): Rf = 0; 1H NMR (400 MHz, (CD3)2SO): δ 8.43 (d, J = 5.0 Hz, 1H), 7.75-
7.71 (m, 3H), 7.51 (d, J = 8.0 Hz, 2H), 7.36 (d, J = 7.5 Hz, 1H), 7.24 (dd, J = 7.0, 5.0 Hz, 1H), 
4.04 (s, 2H), 3.77 (s, 2H); 13C NMR (100 MHz, (CD3)2SO): δ 157.2, 149.2, 148.8, 138.2, 136.7, 
127.5, 126.4, 122.4, 121.6, 47.9, 45.2; HRMS (m/z): [M+H]+ calcd. for C13H15N3O2S, 278.0958; 
found, 278.0948, analysis (calcd., found for C62H56N2O11.0.25H2O): C(73.76, 73.46), H(5.64, 
5.51), N(2.77, 2.79). 
Compound 10. 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (0.5 mmol, 90 µL) was added 
to a stirred solution of Bn4-azotochelin (0.5 mmol, 0.389 g, prepared in accordance to the 
literature46), triethylamine (1 mmol, 0.139 mL) and hydroxybenzotriazole (0.05 mmol, 6.75 mg) 
in 5 mL dry DMF. Subsequently 9 (0.5 mmol, 0.138 g) was added and the solution was stirred 
overnight with a drying tube attached. The DMF was removed in vacuo and the crude product 
was suspended in 75 mL ethyl acetate and washed with 0.1 M HCl (1 x 25 mL), saturated Na-
HCO3 (1 x 25 mL) and brine (1 x 25 mL). The organic layer was dried over MgSO4 and the 
solvent dried in vacuo. The crude product was purified by column chromatography (silicagel, 
100% EtOAc) to afford the pure 10 as an off-white powder (0.244 g, 0.235 mmol, 47%). 
TLC (EtOAc 100%): Rf = 0.17; 1H NMR (400 MHz, CDCl3): δ 8.43 (d, J = 7.0 Hz, 1H), 8.39 (d, J 
= 4.5 Hz, 1H) 7.95 (t, J = 5.5 Hz, 1H), 7.70 (d, J = 8 Hz, 2H), 7.63 (dt, J = 7.0, 3.0 Hz, 2H), 
7.54 (td, J = 8.0, 1.5 Hz, 1H), 7.49-7.24 (m, 23H), 7.18-7.08 (m, 6H), 6.23 (m, 1H), 5.14 (app s, 
 
4H), 5.10 (s, 2H), 5.04 (s, 2H), 4.46 (q, J = 7.0 Hz, 1H), 4.40 (d, J = 6.5 Hz, 2H), 4.18 (d, J = 
2.5 Hz, 2H), 3.14 (q, J = 6.5 Hz, 2H), 1.70 (app sext., J = 7.5 Hz, 1H), 1.39-1.12 (m, 5H); 13C 
NMR (100 MHz, CDCl3): δ 171.7, 165.7, 165.0, 154.8, 151.7, 151.6, 148.8, 146.8, 146.6, 
143.5, 138.3, 136.7, 136.3, 136.3, 136.1, 136.0, 128.9, 128.7, 128.7, 128.6, 128.6, 128.3, 
128.2, 127.8, 127.7, 127.6, 127.3, 127.1, 126.3, 124.4, 124.4, 123.1, 122.9, 122.5, 121.9, 
117.3, 116.8, 76.3, 76.1, 71.3, 71.2, 53.6, 47.4, 42.6, 39.0, 30.6, 28.8, 23.1; HRMS (m/z): 
[M+H]+ calcd. for C61H59N5O9S, 1038.4106; found, 1038.4114; analysis (calcd., found for 
C61H59N5O9S.0.5H2O): C(69.96, 70.02), H(5.77, 5.74), N(6.69, 6.51).  
Compound 11. Reaction glassware was prepared by soaking in 6 M HCl for 4 hours, followed 
by potassium hydroxide in EtOH to remove any residual metal ions. To a solution of 10 (0.09 
mmol, 93 mg) dissolved in dry ethanol, palladium hydroxide 20% on carbon (0.1 mmol, 70 mg) 
was added. The vessel was purged with nitrogen, followed by hydrogen and then filled with 
hydrogen. The reaction was stirred vigorously overnight. The remaining hydrogen was re-
leased and the suspension filtered using a Whatman® Glass Microfiber Filter GF/F. The or-
ganic solvent was removed in vacuo to yield 11 as a beige solid (57.7 mg, 0.085 mmol, 95%). 
TLC (EtOAc, 100%): Rf = 0; 1H NMR (400 MHz, CD3OD): δ 8.34 (d, J = 6.0 Hz, 1H), 7.74 (d, J 
= 8.4 Hz, 2H), 7.68 (td, J = 7.8, 2 Hz, 1H), 7.43 (d, J = 8.4 Hz, 2H), 7.36-7.32 (m, 2H), 7.22-
7.17 (m, 2H), 6.94-6.90 (m, 2H), 6.73-6.66 (m, 2H), 4.60-4.57 (m, 1H), 4.48-4.39 (m, 2H), 4.15 
(s, 2H), 3.61 (q, J = 7.0, 1.8H, EtOH), 3.39 (t, J = 7.0 Hz, 2H), 1.98-1.85 (m, 2H), 1.72-1.64 (m, 
2H), 1.59-1.48 (m, 2H), 1.18 (t, J = 7.0 Hz, 2.8H, EtOH); 13C NMR (100 MHz, CD3OD): δ 
173.4, 170.2, 169.8, 156.9,148.9, 148.4, 148.2, 146.0, 145.9, 143.9, 139.1, 137.5, 127.6, 
126.9, 122.7, 122.2, 118.5, 118.3, 118.2, 117.3, 115.7, 115.5, 57.0 (EtOH), 53.9, 47.5, 42.2, 
38.8, 31.3, 28.7, 23.1, 17.05 (EtOH); HRMS (m/z): [M-H]- calcd. for C33H34N5O9S, 676.2083; 
found, 676.2067; analysis (calcd., found for C33H35N5O9S.0.8EtOH.1.8H2O.0.2KCl): C(54.54, 
54.89), H(5.74, 5.45), N(9.19, 8.84). 
 
Compound 12. [Ir(Cp*)(Cl)2]2 (0.1 mmol, 0.0799 g, prepared in accordance with the 
literature47) was dissolved in 2 mL dichloromethane and added to a stirred solution of 8 (0.2 
mmol, 0.0550 g) in 1 mL dichloromethane. Sodium hydroxide (0.1 mL, 2.0 M methanolic) was 
added to give a pale orange/yellow solution, which was stirred for one hour. The solution was 
filtered and the solvent removed in vacuo to give an orange solid, which was washed with di-
ethyl ether (3 x 5 mL) to yield 12 as a pale orange solid (0.0743 g, 0.11 mmol, 55%). 
1H NMR (400 MHz, CDCl3): δ 8.54 (d, J = 5.5 Hz, 1H), 8.15 (d, J = 8.5 Hz, 2H), 7.72 (app. t, J 
= 7.5 Hz, 1H), 7.58 (d, J = 8.0 Hz, 2H), 7.29-7.23 (m, 2H), 4. 85 (d, J = 17.0 Hz, 1H), 4.54 (d, J 
= 17.0 Hz, 1H), 1.73 (s, 15H). 13C NMR (100 MHz, CDCl3): δ 163.9, 151.5, 148.0, 138.5, 
132.4, 129.2, 125.2, 120.7, 118.7, 114.1, 87.1, 57.8, 9.8; IR (ATIR): 2230 cm-1 (CN); HRMS 
(m/z): [M-Cl]+ calcd. for 191IrC23H25N3O2S, 598.1268; found, 598.1268. 
 
The 1H and 13C NMR spectra of compounds 8-12 are shown in Supplementary Fig. 10. 
Site-directed mutagenesis and purification of CeuE. The plasmid encoding N-terminal 
hexahistidine-tagged CeuE used in previous studies30 was isolated from E. coli NovaBlue 
competent cells (Merck Chemicals Ltd) using a Wizard® Genomic DNA Purification kit 
(Promega). Site-directed mutagenesis was performed in a 25 µl reaction containing Kod Hot 
start DNA polymerase (0.5 U), dNTPs (200 µM), MgSO4 (1 mM), plasmid DNA (1 ng), forward 
primer (5’-CTGTTCCAGGGACCAGCATTGTTGCCTATTAGTA) (400 µM), reverse primer (5’-
TACTAATAGGCAACAATGCTGGTCCCTGGAACAG) (400 µM), and 1 x Kod PCR buffer. The 
PCR cycle was performed at 94°C for 2 minutes, followed by 18 cycles of 94 °C for 30 s, 60 °C 
for 30 s, and 72°C for 3 minutes, followed by a final extension at 72 °C for 5 minutes. The 
template DNA was removed by addition of 2 µL of CutSmart® buffer and 1µL DpnI (20 U/µL) 
to 20 µL of PCR reaction followed by incubation at 37 °C for 2 hours. The final PCR product 
was transformed into NovaBlue competent cells. Mutagenesis was confirmed by isolation and 
 
sequencing of the plasmid from several bacterial colonies using a T7 promoter primer (Eu-
rofins MWG operon). Protein from mutated plasmids was expressed in E. coli BL21 (DE3) 
cells grown in Luria-Bertani broth with 50 µg/mL kanamycin. Cultures were grown at 37 °C with 
shaking at 200 rpm. When the OD600 reached 0.6, protein expression was induced by addition 
of 1 mM IPTG to cultures. Cultures were further incubated for 4 hours and cells were harvest-
ed by centrifugation. Cell pellets were resuspended 1:10 (w/v) in 50 mM Tris-Cl pH 7.5, 500 
mM NaCl, 10 mM imidazole with cOmpleteTM EDTA-free Protease Inhibitor Cocktail (Roche 
Diagnostics) followed by sonication. The lysate was cleared of insoluble material by centrifuga-
tion at 38,000 x g, 4°C for 40 min followed by filtration of supernatant through a 0.4 µm syringe 
filter. The filtered sample was loaded onto a 5 mL HisTrapTM FF Ni-chelating column (GE 
healthcare) and eluted using an imidazole gradient (final concentration of 500 mM) on a Bio-
Rad NGCTM chromatography system. The N-terminal histidine tag was removed by addition of 
2 mg of 3C protease to 100 mg of eluate, followed by dialysis in 3 L of 40 mM Tris-Cl pH 7.5, 
150 mM NaCl at 4°C for 16 h. Residual traces of His-tagged CeuE and 3C protease were re-
moved from the sample by repeating the Ni-affinity purification step. Protein samples were dia-
lysed twice in 2 L of 100 mM MES pH 6, 500 mM NaCl at 4°C for 20 h. Protein was concen-
trated to 60 mg/mL in an Amicon centrifugation filter unit (Millipore), separated into 50 µL ali-
quots and stored at -80 °C. Protein purity and integrity was confirmed by SDS-PAGE and UV-
CD. 
CeuE with a mutation at the histidine at position 227 to alanine was prepared as described in a 
previous study.43 
Preparation of the artificial transfer hydrogenase [FeIII(11)Cp*IrIII]⊂CeuE. First, 
[FeIII(solv)2(11)Cp*IrIIICl]- was formed by adding 60 µL of a 10 mM Fe(III)-NTA solution 
(prepared as previously described29) to 18 µL of 200 mM MOPS pH 7.5, 150 mM NaCl and 
 
incubation in a sonication bath for 10 minutes. Following this, 11 (12 µL, 50 mM in DMF) was 
added and the mixture was sonicated for 10 minutes. Then, [Cp*IrIIICl2]2 (30 µL, 10 mM in 
DMF) was added and the mixture was sonicated for 10 minutes. [FeIII(11)Cp*IrIII]⊂CeuE was 
subsequently formed by addition of 250 µL of 60 mg/ml CeuE to 15 mL of 100 mM MES pH 6, 
500 mM NaCl, followed by addition of 96.5 µL of the [FeIII(solv)2(11)Cp*IrIIICl]- solution. The 
resulting solution was concentrated in a Vivaspin 20 centrifugation filter unit (3 kDa MWCO) 
and the protein concentration was determined using a PierceTM Coomassie Plus (Bradford) 
Assay kit (Thermofisher) using BSA as a standard. 
 
Catalytic activity testing: 
General. 6,7-dimethoxy-1-methyl-3,4-dihydroisoquinoline was purchased from Acros. Analyti-
cal HPLC measurements were performed on a Shimadzu HPLC system (Prominence) 
equipped with a LC-20AD pump, SIL-20A autosampler, DGU-20AS degasser, CTO-20AC col-
umn oven, CBM-20A communication bus module and SPD-M20A diode array detector using a 
Lux Cellulose-4 column (Phenomenex, 250 mm x 4.6 mm, 5 µm) with the specified eluent gra-
dient. 
Stock solutions. MES/formate buffer: 6.40 g of 2-morpholin-4-ylethanesulfonic acid monohy-
drate (MES monohydrate) and 10.20 g of sodium formate were dissolved in 40 mL water and 
the pH adjusted by addition of NaOH, before the solution volume was finalised at 50 mL (final 
concentration 0.6 M MES, 3 M formate). Substrate: 0.2053 g of 6, 7-dimethoxy-1-methyl-3,4-
dihydroisoquinoline was dissolved in 2 mL of MES/formate buffer (final concentration 0.5 M). 
Compound 11: 3.39 mg of 11 was dissolved in 500 µL DMF (final concentration 10 mM). Glu-
tathione: 76.8 mg of glutathione was dissolved in 1 mL of water (final concentration 250 mM). 
 
Catalyst. 10 mM stock solutions of the required catalysts were prepared in situ by mixing 
[IrCp*Cl2]2 with the appropriate ligand in DMF. 
 
General procedure. 6,7-dimethoxy-1-methyl-3,4-dihydroisoquinoline (50 mM) and 0.125 mM 
catalyst in 0.6 M MES pH 6, 3 M sodium formate incubated at 40°C with a magnetic stirrer set 
to 400 rpm. Reactions were initiated by addition of the substrate and 25 µL samples were tak-
en at selected time points and quenched by adding to 975 µL of L-glutathione (50 µL of 250 
mM L-glutathione stock diluted in 300 µL water and 625 µL MeOH). Samples were left to stand 
for 1 hour at 4 °C before being filtered through 0.22 µm nylon membranes. Reaction progres-
sion was monitored via HPLC (see HPLC method below for further details). Peaks that repre-
sented substrate and product with an absorbance at 285 nm were integrated and used to cal-
culate normalised product percentages. 
 
HPLC method. Solvent A: H2O + 0.1% DEA, solvent B : MeCN + 0.1% DEA. The starting ratio 
was 75:25 (A:B) and was maintained for 12 minutes. Ramp to 35:65 (A:B) at 12 minutes over 
0.5 minutes and held for 2.5 minutes. At 15 minutes the solvent was ramped back to 75:25 
(A:B) over 0.5 minutes amd held until 35 minutes. 1 mL/min, 35 °C; TR (S)-(-)-Salsolidine 11.5 
min, (R)-(+)-Salsolidine 12.5 min, 6,7-dimethoxy-1-methyl-3,4-dihydroisoquinoline 15.5 min. 
 
Data availability. Experimental details of circular dichroism spectroscopic measurements (Fig. 
4b), intrinsic fluorescence quenching titrations (Fig. 4a), mass spectrometry measurements, 
crystal structure determinations (Fig. 4c-e) and reversibility studies (Figs. 2, 6) are described in 
the Supplementary Methods. X-ray crystallographic data are available in the EMBL-EBI PDB 
under the accession numbers 5OAH ([FeIII(AZOTO)]2-⊂CeuE) and 5OD5 
[FeIII(11)Cp*IrIII]⊂CeuE and the Cambridge Crystallographic Data Centre deposition number 
 
CCDC 1551724 (12). Other supporting data were deposited with the University of York library 
(www.york.ac.uk/library/info-for/researchers/datasets/) under DOI: 10.15124/233cf8cc-d25a-
4793-b667-7557836774c1 or are available from the authors upon reasonable request. 
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